Doximity (NYSE: DOCS) Stock Downgraded by Wells Fargo Amid Profit Pressure and AI Investments

• Wells Fargo (NYSE: WFC) downgraded Doximity (NYSE: DOCS) to Equal Weight, setting a price target of $18.00, representing a potential 23.04% downside.
• Despite strong fiscal fourth-quarter revenue of $145.37 million (5% year-over-year increase) and record $107 million in quarterly free cash flow, profitability is pressured, with quarterly earnings of $0.26 per share missing estimates.
• The company's "AI investment year" is impacting financials, leading to a decline in non-GAAP gross margin from 91% to 89% due to AI compute costs.

Doximity (NYSE: DOCS) is a leading digital platform for U.S. medical professionals, providing essential tools for communication, telehealth, and industry news. On May 14, 2026, Wells Fargo (NYSE: WFC), a prominent financial institution, downgraded the healthcare technology company to Equal Weight from Overweight. The bank set a new price target of $18.00, which was a potential 23.04% downside from the stock's price of $23.39 at the time.

This analyst downgrade comes despite some strong top-line growth for Doximity. The company announced fiscal fourth-quarter revenue of $145.37 million, a 5% year-over-year increase. For the full fiscal year 2026, revenue grew 13% to $645 million. Doximity also generated a record $107 million in quarterly free cash flow, which is the cash a company produces after accounting for cash outflows to support operations.

However, profitability shows signs of pressure, which may explain the more cautious outlook. As highlighted by Zacks, a well-known investment research firm, Doximity reported quarterly earnings of $0.26 per share, missing analyst estimates of $0.28 per share. This figure also represents a notable decrease from the $0.38 per share reported in the same quarter a year ago, signaling potential challenges for the telehealth platform.

Management stated that Doximity is entering an "AI investment year," leading to higher spending on artificial intelligence initiatives. This strategic investment is already impacting financials, with the company attributing a decline in its non-GAAP gross margin to 89% from 91% a year earlier to AI compute costs. This margin shows the percentage of revenue left after subtracting the cost of goods sold.

Reflecting these mixed financial results and future spending plans, the market reacted negatively. Shares of Doximity fell $3.06, or 11.57%, to $23.39 on the day of the announcement. This significant price movement shows that investors share some of the concerns that likely led to the analyst downgrade, impacting the DOCS stock performance.